<DOC>
	<DOCNO>NCT02791269</DOCNO>
	<brief_summary>This expand access , multicenter , national , open-label , non-randomized study analyze safety peginterferon alfa-2a participant hepatitis B e antigen ( HBeAg ) positive HBeAg negative chronic HBV infection . All participant receive 48 week treatment peginterferon alfa-2a monotherapy , follow 24 week treatment-free follow-up period .</brief_summary>
	<brief_title>A Study Peginterferon Alfa-2a Participants With Chronic Hepatitis B Virus ( HBV ) Expanded Access Program</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Noncirrhotic participant Hepatitis B surface antigen ( HBsAg ) positive least 6 month Hepatitis B surface antibody ( antiHBs ) negative Elevated serum alanine aminotransferase ( ALT ) great ( &gt; ) upper limit normal ( ULN ) less equal ( &lt; /= ) 10 time ULN HBeAg positive participant : HBV DNA &gt; 500,000 copies/mL , HBeAg negative participant : HBV DNA &gt; 100,000 copies/mL polymerase chain reaction ( PCR ) Participants chronic hepatitis B ( CHB ) treatmentnaive No previous antiviral treatment interferon ( IFN : standard pegylated ) nucleoside analogue For woman childbearing potential : negative urine serum pregnancy test document within 24hour period prior first dose test drug . Willingness use reliable contraception study 3 month treatment completion Previous antiviral IFNbased therapy CHB enrolment Pregnant breast feed woman participant Evidence decompensated liver disease Coinfection active hepatitis A , hepatitis C , hepatitis D and/or human immunodeficiency virus ( HIV ) History evidence medical condition associate chronic liver disease viral hepatitis Previous current hepatocellular carcinoma History evidence bleed esophageal varix condition consistent decompensated liver disease Alphafetoprotein level &gt; 100 nanogram ( ng ) /mL Severe psychiatric disease History severe seizure disorder current anticonvulsant use History immunologically mediate disease , chronic pulmonary disease associate functional limitation , severe cardiac disease , major organ transplantation evidence severe illness , malignancy , condition would make participant , opinion investigator , unsuitable study Thyroid disease uncontrolled prescribed medication Evidence severe retinopathy Alcohol intake 3 standard drink per day men 2 standard drink per day woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>